Editing Triptan (section)

===Comparison===
{| class="wikitable" style="margin: 1em auto 1em auto;"
|+ Comparative pharmacology of triptans, oral formulations<ref name="Goodman" /><ref name="Bigal"/><ref name="Armstrong"/><ref name="Mathew"/>
|-
! Drug !! Brand !! Company !! Receptor agonist !! 5-HT<sub>1D</sub> affinity<br/>(pKI in [[nanomolar|nM]])<ref name="Deleu">{{cite journal|title=Current and emerging second-generation triptans in acute migraine therapy: a comparative review|journal=J Clin Pharmacol|author1=Deleu, D. |author2=Hanssens Y. |year=2000|volume=40|issue=7|pages=687–700|pmid=10883409|doi=10.1177/00912700022009431|s2cid=15585554}}</ref> !! [[Bioavailability|Bioavail&shy;ability]] (%) !! [[Partition coefficient|log D<sub>pH 7.4</sub>]] !! [[Cmax (pharmacology)|T<sub>max</sub>]] (h) !! [[Elimination half-life|T<sub>1/2</sub>]] (h) !! Metab&shy;olism !! Dose (mg)
|-
| [[Sumatriptan]] 
| align="center"| Imitrex
| align="center"| [[Glaxo Smith Kline]]
| align="center"| 5-HT<sub>1B/D</sub>
| align="center"| 7.9–8.5
| align="center"| 14–17
| align="center"| –1.3
| align="center"| 2–2.5
| align="center"| 2.5
| align="center"| [[MAO-A]]
| align="center"| 25, <br /> 50, <br /> 100
|-
| [[Zolmitriptan]] 
| align="center"| Zomig
| align="center"| [https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html Grünenthal]<ref>{{Cite web|url=https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html|title=AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig|website=www.astrazeneca.com|date=7 June 2017 |language=en|access-date=2018-03-22|url-status=live|archive-url=https://web.archive.org/web/20180322204845/https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html|archive-date=2018-03-22}}</ref>
| align="center"| 5-HT<sub>1B/D</sub>
| align="center"| 9.2
| align="center"| 40
| align="center"| –0.7
| align="center"| 1.5–2
| align="center"| 2–3
| align="center"| [[MAO-A]] <br /> [[CYP1A2]]
| align="center"| 2.5, <br /> 5
|-
| [[Naratriptan]] 
| align="center"| Amerge
| align="center"| [[Glaxo Smith Kline]]
| align="center"| 5-HT<sub>1B/D</sub>
| align="center"| 8.3
| align="center"| 70
| align="center"| –0.2
| align="center"| 2–3
| align="center"| 6
| align="center"| many CYPs <br /> [[MAO-A]]
| align="center"| 1, <br /> 2.5
|-
| [[Rizatriptan]] 
| align="center"| Maxalt
| align="center"| Merck
| align="center"| 5-HT<sub>1B/D</sub>
| align="center"| 7.7
| align="center"| 45
| align="center"| –0.7
| align="center"| 1–1.5
| align="center"| 2–2.5
| align="center"| [[MAO-A]]
| align="center"| 5, <br /> 10
|-
| [[Almotriptan]] 
| align="center"| Axert
| align="center"| Almirall-Prodesfarma
| align="center"| 5-HT<sub>1B/D</sub> <br /> 5-HT<sub>1F</sub>{{citation needed|date=October 2016}}
| align="center"| 7.8
| align="center"| 70
| align="center"| +0.35
| align="center"| 2.5
| align="center"| 3.6
| align="center"| [[CYP2D6]] <br /> [[CYP3A4]] <br /> [[MAO-A]]
| align="center"| 6.25, <br /> 12.5
|-
| [[Eletriptan]] 
| align="center"| Relpax
| align="center"| [[Pfizer]]
| align="center"| 5-HT<sub>1B/D</sub> <br /> 5-HT<sub>1F</sub><ref name=relpax_spc>{{cite web | title= Relpax – 20 mg and 40 mg | url= http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=8195 | access-date= 2008-11-09 | url-status= live | archive-url= https://web.archive.org/web/20040620163458/http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=8195 | archive-date= 2004-06-20 }}</ref>
| align="center"| 8.9
| align="center"| 50
| align="center"| +0.5
| align="center"| 1–2
| align="center"| 3.6–5.5
| align="center"| [[CYP3A4]]
| align="center"| 20, <br /> 40, <br /> 80
|-
| [[Frovatriptan]]
| align="center"| Frova
| align="center"| Vernalis
| align="center"| 5-HT<sub>1B/D</sub>
| align="center"| 8.4
| align="center"| 24–30
| align="center"| 
| align="center"| 2–4
| align="center"| 26
| align="center"| [[CYP1A2]]
| align="center"| 2.5
|}

Zolmitriptan is different from the other triptans because it is converted to an active N-desmethyl metabolite which has higher affinity for the 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors; both substances have a biological half-life of 2 to 3 hours.<ref name="Goodman" /> In studies, newer triptans are mostly compared to sumatriptan.<ref name="Ferrari">{{cite journal | last1 = Ferrari | first1 = M. D. | last2 = Goadsby | first2 = P. J. | last3 = Roon | first3 = K. I. | last4 = Lipton | first4 = R. B. | year = 2002 | title = Triptan (serotonin, 5-HT1D/1B agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials | journal = Cephalalgia | volume = 22 | issue = 8| pages = 633–658 | doi = 10.1046/j.1468-2982.2002.00404.x | pmid=12383060| s2cid = 2368571 }}</ref> They are better than sumatriptan for their longer half-life in plasma and higher oral [[bioavailability]],<ref name="Foyes" /> but have a higher potential for [[central nervous]] side effects.<ref name="Mutschler" />

[[Donitriptan]] and [[avitriptan]] were never marketed.